List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9381620/publications.pdf

Version: 2024-02-01

		34076	33869
179	11,305	52	99
papers	citations	h-index	g-index
182	182	182	9742
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Circulating GDF15 concentrations in girls with low birth weight: effects of prolonged metformin treatment. Pediatric Research, 2023, 93, 964-968.	1.1	2
2	A 24â€month metformin treatment study of children with obesity: Changes in circulating <scp>GDF</scp> â€15 and associations with changes in body weight and visceral fat. Pediatric Obesity, 2022, 17, e12845.	1.4	3
3	Posterior Cervical Brown Fat and CXCL14 Levels in the First Year of Life: Sex Differences and Association With Adiposity. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1148-e1158.	1.8	6
4	microRNAs in newborns with low birth weight: relation to birth size and body composition. Pediatric Research, 2022, 92, 829-837.	1.1	5
5	Bone Morphogenetic Protein-8B Levels at Birth and in the First Year of Life: Relation to Metabolic-Endocrine Variables and Brown Adipose Tissue Activity. Frontiers in Pediatrics, 2022, 10, 869581.	0.9	3
6	Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments. Pediatric Obesity, 2021, 16, e12734.	1.4	16
7	Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss. Hepatology, 2021, 73, 1623-1624.	3.6	5
8	Development of a sensitive analytical method for the simultaneous analysis of Benzophenone-type UV filters and paraben preservatives in umbilical cord blood. MethodsX, 2021, 8, 101307.	0.7	10
9	The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Scientific Reports, $2021, 11, 7018$.	1.6	10
10	Catch-up growth in juvenile rats, fat expansion, and dysregulation of visceral adipose tissue. Pediatric Research, 2021, , .	1.1	4
11	Circulating diazepamâ€binding inhibitor in infancy: Relation to markers of adiposity and metabolic health. Pediatric Obesity, 2021, 16, e12802.	1.4	1
12	From adolescent PCOS to adult MAFLD: opposing effects of randomised interventions. BMJ Open Gastroenterology, 2021, 8, e000574.	1.1	5
13	Estimated glomerular filtration rate and cardiometabolic risk factors in a longitudinal cohort of children. Scientific Reports, 2021, 11, 11702.	1.6	5
14	Fatty acids in the placenta of appropiate- versus small-for-gestational-age infants at term birth. Placenta, 2021, 109, 4-10.	0.7	8
15	On the rising incidence of early breast development: puberty as an adaptive escape from ectopic adiposity in mismatch girls. European Journal of Endocrinology, 2021, 185, L1-L2.	1.9	8
16	Longitudinal association of the anti-inflammatory serum marker GDF-15 with serum IgA and IgG in apparently healthy children. Scientific Reports, 2021, 11, 18215.	1.6	1
17	Methylation of the C19MC microRNA locus in the placenta: association with maternal and chilhood body size. International Journal of Obesity, 2020, 44, 13-22.	1.6	10
18	Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal growth and adiposity measurements. Pediatric Research, 2020, 87, 897-902.	1.1	17

#	Article	IF	Citations
19	Polycystic ovary syndrome in adolescent girls. Pediatric Obesity, 2020, 15, e12586.	1.4	19
20	Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e273-e281.	1.8	19
21	Differential DNA methylation profile in infants born small-for-gestational-age: association with markers of adiposity and insulin resistance from birth to age 24 months. BMJ Open Diabetes Research and Care, 2020, 8, e001402.	1.2	14
22	Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial. Nutrients, 2020, 12, 3123.	1.7	12
23	Specific Dietary Components and Gut Microbiota Composition are Associated with Obesity in Children and Adolescents with Prader–Willi Syndrome. Nutrients, 2020, 12, 1063.	1.7	17
24	Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome. Journal of the Endocrine Society, 2020, 4, bvaa032.	0.1	21
25	Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization. BMJ Open Diabetes Research and Care, 2020, 8, e001035.	1.2	19
26	Towards a simple marker of hepatoâ€visceral adiposity and insulin resistance: The Zâ€score change from weightâ€atâ€birth to BMIâ€inâ€childhood. Pediatric Obesity, 2019, 14, e12533.	1.4	11
27	Umbilical Cord miRNAs in Small-for-Gestational-Age Children and Association With Catch-Up Growth: A Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5285-5298.	1.8	21
28	Towards a circulating marker of hepatoâ€visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome â€" Evidence from randomized clinical trials. Pediatric Obesity, 2019, 14, e12500.	1.4	9
29	Dlk1 expression relates to visceral fat expansion and insulin resistance in male and female rats with postnatal catch-up growth. Pediatric Research, 2019, 86, 195-201.	1.1	5
30	Renal size and cardiovascular risk in prepubertal children. Scientific Reports, 2019, 9, 5265.	1.6	6
31	Exploring the use of metformin in pregnant women with polycystic ovary syndrome: new evidence, new wisdom. Lancet Diabetes and Endocrinology,the, 2019, 7, 242-243.	5.5	1
32	Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study. PLoS ONE, 2019, 14, e0226303.	1.1	25
33	Brown adipose tissue in prepubertal children: associations with sex, birthweight, and metabolic profile. International Journal of Obesity, 2019, 43, 384-391.	1.6	25
34	Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation. Hormone Research in Paediatrics, 2018, 89, 136-140.	0.8	17
35	Nerve Growth Factor Levels in Term Human Infants: Relationship to Prenatal Growth and Early Postnatal Feeding. International Journal of Endocrinology, 2018, 2018, 1-6.	0.6	7
36	Central Obesity, Faster Maturation, and â€~PCOS' in Girls. Trends in Endocrinology and Metabolism, 2018, 29, 815-818.	3.1	57

#	Article	IF	Citations
37	Pediatric endocrinology: an overview of the last decade. Hormones, 2018, 17, 439-449.	0.9	1
38	Circulating sex hormone binding globulin: An integrating biomarker for an adverse cardio-metabolic profile in obese pregnant women. PLoS ONE, 2018, 13, e0205592.	1.1	14
39	Serum 25-hydroxyvitamin D and cardiovascular disease risk factors in women with excessive weight gain during pregnancy and in their offspring at age 5–6 years. International Journal of Obesity, 2018, 42, 1019-1028.	1.6	1
40	Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome. International Journal of Endocrinology, 2018, 2018, 1-5.	0.6	8
41	The placental imprinted DLK1-DIO3 domain: a new link to prenatal and postnatal growth in humans. American Journal of Obstetrics and Gynecology, 2017, 217, 350.e1-350.e13.	0.7	23
42	Dysregulation of Placental miRNA in Maternal Obesity Is Associated With Pre- and Postnatal Growth. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2584-2594.	1.8	59
43	Placental and Cord Blood Methylation of Genes Involved in Energy Homeostasis: Association With Fetal Growth and Neonatal Body Composition. Diabetes, 2017, 66, 779-784.	0.3	62
44	Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome. Journal of Adolescent Health, 2017, 61, 446-453.	1.2	34
45	Reduced Prenatal Weight Gain and/or Augmented Postnatal Weight Gain Precedes Polycystic Ovary Syndrome in Adolescent Girls. Obesity, 2017, 25, 1486-1489.	1.5	35
46	An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Hormone Research in Paediatrics, 2017, 88, 371-395.	0.8	282
47	eRah: A Computational Tool Integrating Spectral Deconvolution and Alignment with Quantification and Identification of Metabolites in GC/MS-Based Metabolomics. Analytical Chemistry, 2016, 88, 9821-9829.	3.2	101
48	Large for Gestational Age Newborns from Mothers Without Diabetes Mellitus Tend to Become Tall and Lean Toddlers. Journal of Pediatrics, 2016, 178, 278-280.	0.9	7
49	Circulating Fatty Acid Synthase in pregnant women: Relationship to blood pressure, maternal metabolism and newborn parameters. Scientific Reports, 2016, 6, 24167.	1.6	10
50	Determination of parabens and benzophenone-type UV filters in human placenta. First description of the existence of benzyl paraben and benzophenone-4. Environment International, 2016, 88, 243-249.	4.8	114
51	Metabolomics reveals impaired maturation of HDL particles in adolescents with hyperinsulinaemic androgen excess. Scientific Reports, 2015, 5, 11496.	1.6	15
52	Neutrophil-to-lymphocyte ratio: an inflammation marker related to cardiovascular risk in children. Thrombosis and Haemostasis, 2015, 114, 727-734.	1.8	20
53	Relationship between Foetal Growth Restriction and Maternal Nutrition Status Measured by Dual-Energy X-Ray Absorptiometry, Leptin, and Insulin-Like Growth Factor. Gynecologic and Obstetric Investigation, 2015, 80, 54-59.	0.7	9
54	The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Hormone Research in Paediatrics, 2015, 83, 376-389.	0.8	2,130

#	Article	IF	Citations
55	Altered Circulating miRNA Expression Profile in Pregestational and Gestational Obesity. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1446-E1456.	1.8	80
56	Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. Pediatric Diabetes, 2015, 16, 538-545.	1.2	23
57	Placental Sprouty 2 <i>(SPRY2)</i> : Relation to Placental Growth and Maternal Metabolic Status. Neonatology, 2014, 106, 120-125.	0.9	2
58	Less Myostatin and More Lean Mass in Large-Born Infants From Nondiabetic Mothers. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2367-E2371.	1.8	9
59	Mitochondrial DNA in Placenta: Associations with Fetal Growth and Superoxide Dismutase Activity. Hormone Research in Paediatrics, 2014, 82, 303-309.	0.8	21
60	Associations Between Genetic Obesity Susceptibility and Early Postnatal Fat and Lean Mass. JAMA Pediatrics, 2014, 168, 1122.	3.3	41
61	Balanced duo of anti-inflammatory SFRP5 and proinflammatory WNT5A in children. Pediatric Research, 2014, 75, 793-797.	1.1	19
62	Hyperinsulinaemic androgen excess in adolescent girls. Nature Reviews Endocrinology, 2014, 10, 499-508.	4.3	46
63	Undercarboxylated osteocalcin relates to cardiovascular risk markers in offspring of families with metabolic syndrome. Atherosclerosis, 2014, 233, 272-277.	0.4	22
64	Pituitary dysfunction after traumatic brain injury in children: is there a need for ongoing endocrine assessment?. Clinical Endocrinology, 2013, 79, 853-858.	1.2	30
65	A common gene variant in STK11 is associated with metabolic risk markers and diabetes during gestation. Fertility and Sterility, 2013, 100, 788-792.	0.5	8
66	Oral Contraception vs Insulin Sensitization for 18 Months in Nonobese Adolescents With Androgen Excess: Posttreatment Differences in C-Reactive Protein, Intima-Media Thickness, Visceral Adiposity, Insulin Sensitivity, and Menstrual Regularity. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E902-E907.	1.8	35
67	Breast-feeding vs Formula-feeding for Infants Born Small-for-Gestational-Age: Divergent Effects on Fat Mass and on Circulating IGF-I and High-Molecular-Weight Adiponectin in Late Infancy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1242-1247.	1.8	39
68	Body Composition and Circulating High-Molecular-Weight Adiponectin and IGF-I in Infants Born Small for Gestational Age. Diabetes, 2012, 61, 1969-1973.	0.3	52
69	Ethinyl Estradiol-Cyproterone Acetate <i>Versus</i> Low-Dose Pioglitazone-Flutamide-Metformin for Adolescent Girls with Androgen Excess: Divergent Effects on <i>CD163</i> , <i>TWEAK</i> Receptor, <i>ANGPTL4</i> , and <i>LEPTIN</i> Expression in Subcutaneous Adipose Tissue. Journal of Clinical Endocrinology and Metabolism. 2012, 97, 3630-3638.	1.8	17
70	Abundance of Circulating Preadipocyte Factor 1 in Early Life. Diabetes Care, 2012, 35, 848-849.	4.3	28
71	Triple A Syndrome in a Patient with Genetic Growth Hormone Insensitivity: Phenotypic Effects of Two Genetic Disorders. Hormone Research in Paediatrics, 2012, 77, 63-68.	0.8	10
72	IGF2/H19 hypomethylation in a patient with very low birthweight, preocious pubarche and insulin resistance. BMC Medical Genetics, 2012, 13, 42.	2.1	24

#	Article	IF	Citations
73	On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome $\hat{a}\in \hat{a}$ an epi $\hat{a}\in \hat{a}$ nalysis. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1460-1464.	1.3	27
74	Placental Expression of Peroxisome Proliferator-Activated Receptor \hat{I}^3 (PPAR \hat{I}^3): Relation to Placental and Fetal Growth. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1468-E1472.	1.8	39
75	Carotid Intima-Media Thickness at 7 Years of Age: Relationship to C-Reactive Protein Rather than Adiposity. Journal of Pediatrics, 2012, 160, 276-280.e1.	0.9	17
76	Divergent effects of ethinylestradiolâ€"drospirenone and flutamideâ€"metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess. Gynecological Endocrinology, 2011, 27, 197-198.	0.7	5
77	Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. Gynecological Endocrinology, 2011, 27, 935-939.	0.7	12
78	Pharmacokinetics of Metformin in Girls Aged 9 Years. Clinical Pharmacokinetics, 2011, 50, 735-738.	1.6	14
79	Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertility and Sterility, 2011, 95, 727-730.	0.5	62
80	Catch-up growth in girls born small for gestational age precedes childhood progression to high adiposity. Fertility and Sterility, 2011, 96, 220-223.	0.5	52
81	Responsiveness to metformin in girls with androgen excess: collective influence of genetic polymorphisms. Fertility and Sterility, 2011, 96, 208-213.e2.	0.5	13
82	Flutamide for Androgen Excess: Low Dose is Best. Journal of Pediatric and Adolescent Gynecology, 2011, 24, e43-e44.	0.3	4
83	Toward an Early Marker of Metabolic Dysfunction: Omentinâ€1 in Prepubertal Children. Obesity, 2011, 19, 1905-1907.	1.5	31
84	Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy. PLoS ONE, 2011, 6, e29052.	1.1	41
85	Early Metformin Therapy (Age 8–12 Years) in Girls with Precocious Pubarche to Reduce Hirsutism, Androgen Excess, and Oligomenorrhea in Adolescence. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1262-E1267.	1.8	104
86	Lower Free Thyroxin Associates with a Less Favorable Metabolic Phenotype in Healthy Pregnant Women. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3717-3723.	1.8	73
87	Metabolic Impact of Growth Hormone Treatment in Short Children Born Small for Gestational Age. Hormone Research in Paediatrics, 2011, 76, 254-261.	0.8	23
88	Endocrinology and Gynecology of Girls and Women with Low Birth Weight. Fetal Diagnosis and Therapy, 2011, 30, 243-249.	0.6	41
89	Association of p.His38Leu, a Rare <i>CYP21A2</i> Mutation, with the Classical Simple Virilizing Phenotype of 21-Hydroxylase Deficiency in a 6-Year-Old Boy. Hormone Research in Paediatrics, 2011, 76, 214-217.	0.8	2
90	Treatment of Androgen Excess in Adolescent Girls: Ethinylestradiol-Cyproteroneacetate Versus Low-Dose Pioglitazone-Flutamide-Metformin. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3361-3366.	1.8	31

#	Article	IF	Citations
91	Low Body Adiposity and High Leptinemia in Breast-fed Infants Born Small-for-Gestational-Age. Journal of Pediatrics, 2010, 156, 145-147.	0.9	24
92	Pubertal Metformin Therapy to Reduce Total, Visceral, and Hepatic Adiposity. Journal of Pediatrics, 2010, 156, 98-102.e1.	0.9	39
93	A Single Nucleotide Polymorphism in <i>STK11</i> Influences Insulin Sensitivity and Metformin Efficacy in Hyperinsulinemic Girls With Androgen Excess. Diabetes Care, 2010, 33, 1544-1548.	4.3	31
94	Carboxylation of Osteocalcin Affects Its Association With Metabolic Parameters in Healthy Children. Diabetes Care, 2010, 33, 661-663.	4.3	59
95	Growth Hormone Therapy in Short Children Born Small for Gestational Age: Effects on Abdominal Fat Partitioning and Circulating Follistatin and High-Molecular-Weight Adiponectin. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2234-2239.	1.8	26
96	Association between a Common Variant near MC4R and Change in Body Mass Index Develops by Two Weeks of Age. Hormone Research in Paediatrics, 2010, 73, 275-280.	0.8	13
97	Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormoneâ€"binding globulin and androgen receptor polymorphisms. Fertility and Sterility, 2010, 94, 2800-2803.e1.	0.5	11
98	Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months. Gynecological Endocrinology, 2010, 26, 869-873.	0.7	15
99	Low-dose flutamide for hirsutism: into the limelight, at last. Nature Reviews Endocrinology, 2010, 6, 421-422.	4.3	20
100	Early Origins of Polycystic Ovary Syndrome: Hypotheses May Change without Notice. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3682-3685.	1.8	28
101	Low-Birth Weight Children Develop Lower Sex Hormone Binding Globulin and Higher Dehydroepiandrosterone Sulfate Levels and Aggravate their Visceral Adiposity and Hypoadiponectinemia between Six and Eight Years of Age. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3696-3699.	1.8	68
102	Abdominal Fat Partitioning and High-Molecular-Weight Adiponectin in Short Children Born Small for Gestational Age. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1049-1052.	1.8	44
103	High-Molecular-Weight Adiponectin in Children Born Small- or Appropriate-for-Gestational-Age. Journal of Pediatrics, 2009, 155, 740-742.	0.9	17
104	Clinical spectrum of premature pubarche: Links to metabolic syndrome and ovarian hyperandrogenism. Reviews in Endocrine and Metabolic Disorders, 2009, 10, 63-76.	2.6	85
105	Lowâ€dose pioglitazone and lowâ€dose flutamide added to metformin and oestroâ€progestagens for hyperinsulinaemic women with androgen excess: addâ€on benefits disclosed by a randomized doubleâ€placebo study over 24Âmonths. Clinical Endocrinology, 2009, 71, 351-357.	1.2	27
106	Adipose tissue expandability and the early origins of PCOS. Trends in Endocrinology and Metabolism, 2009, 20, 418-423.	3.1	88
107	Pioglitazone (7·5 mg/day) added to flutamide–metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clinical Endocrinology, 2008, 68, 317-320.	1.2	23
108	Cord serum visfatin at term birth: maternal smoking unmasks the relation to foetal growth. Clinical Endocrinology, 2008, 68, 77-81.	1.2	14

#	Article	IF	Citations
109	Pubertal adiposity after fetal growth restraint: toward a calorie restriction mimetic approach. Metabolism: Clinical and Experimental, 2008, 57, 672-675.	1.5	5
110	Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1105-1120.	1.8	372
111	Early Development of Visceral Fat Excess after Spontaneous Catch-Up Growth in Children with Low Birth Weight. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 925-928.	1.8	135
112	Gender Specificity of Body Adiposity and Circulating Adiponectin, Visfatin, Insulin, and Insulin Growth Factor-I at Term Birth: Relation to Prenatal Growth. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2774-2778.	1.8	90
113	Polycystic Ovaries in Nonobese Adolescents and Young Women with Ovarian Androgen Excess: Relation to Prenatal Growth. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 196-199.	1.8	34
114	Visceral Adiposity without Overweight in Children Born Small for Gestational Age. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2079-2083.	1.8	137
115	Metformin Treatment for Four Years to Reduce Total and Visceral Fat in Low Birth Weight Girls with Precocious Pubarche. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1841-1845.	1.8	76
116	The Association between the FTO Gene and Fat Mass in Humans Develops by the Postnatal Age of Two Weeks. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1501-1505.	1.8	110
117	Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1710-1714.	1.8	51
118	Improvement in Growth after Two Years of Growth Hormone Therapy in Very Young Children Born Small for Gestational Age and without Spontaneous Catch-Up Growth: Results of a Multicenter, Controlled, Randomized, Open Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3095-3101.	1.8	44
119	Flutamide–metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype. European Journal of Endocrinology, 2007, 157, 661-668.	1.9	13
120	Lack of association between common polymorphisms in the $17\hat{l}^2$ -hydroxysteroid dehydrogenase type V gene (HSD17B5) and precocious pubarche. Journal of Steroid Biochemistry and Molecular Biology, 2007, 105, 176-180.	1.2	16
121	Insulin resistance after precocious pubarche: relation to PAI-1?675 4G/5G polymorphism, and opposing influences of prenatal and postnatal weight gain. Clinical Endocrinology, 2007, 67, 070607050851001-???.	1.2	3
122	Persisting benefits 12?18�months after discontinuation of pubertal metformin therapy in low birthweight girls. Clinical Endocrinology, 2007, 67, 468-471.	1.2	20
123	Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women. Fertility and Sterility, 2006, 86, S24-S25.	0.5	12
124	Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertility and Sterility, 2006, 86, S4-S5.	0.5	56
125	Puberty and prenatal growth. Molecular and Cellular Endocrinology, 2006, 254-255, 22-25.	1.6	60
126	Associations between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations. Journal of Steroid Biochemistry and Molecular Biology, 2006, 98, 199-206.	1.2	16

#	Article	IF	CITATIONS
127	Discontinuous low-dose flutamide–metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-α and the neutrophil/lymphocyte ratio. Human Reproduction, 2006, 21, 451-456.	0.4	27
128	Early Development of Adiposity and Insulin Resistance after Catch-Up Weight Gain in Small-for-Gestational-Age Children. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2153-2158.	1.8	491
129	Metformin Therapy during Puberty Delays Menarche, Prolongs Pubertal Growth, and Augments Adult Height: A Randomized Study in Low-Birth-Weight Girls with Early-Normal Onset of Puberty. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2068-2073.	1.8	113
130	Early Puberty-Menarche After Precocious Pubarche: Relation to Prenatal Growth. Pediatrics, 2006, 117, 117-121.	1.0	164
131	Metformin Treatment to Prevent Early Puberty in Girls with Precocious Pubarche. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2888-2891.	1.8	119
132	Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Human Reproduction Update, 2006, 12, 243-252.	5.2	89
133	Effects of Growth Hormone Treatment on Neutrophil Count in Children Born Small for Gestational Age. Pediatrics, 2006, 117, 1868-1869.	1.0	6
134	Neutrophil Count in Small-for-Gestational Age Children: Contrasting Effects of Metformin and Growth Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3435-3439.	1.8	46
135	High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Human Reproduction, 2005, 20, 2457-2462.	0.4	76
136	Flutamide-Metformin plus Ethinylestradiol-Drospirenone for Lipolysis and Antiatherogenesis in Young Women with Ovarian Hyperandrogenism: The Key Role of Metformin at the Start and after More than One Year of Therapy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 39-43.	1.8	60
137	Hyperandrogenism and Excess Weight Gain. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 1199-205.	0.4	2
138	Absent or Delayed Adrenarche in Pit-1/POU1F1 Deficiency. Hormone Research in Paediatrics, 2005, 64, 175-179.	0.8	23
139	Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Human Reproduction, 2005, 20, 1833-1836.	0.4	54
140	Insulin Sensitization for Girls with Precocious Pubarche and with Risk for Polycystic Ovary Syndrome: Effects of Prepubertal Initiation and Postpubertal Discontinuation of Metformin Treatment. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4331-4337.	1.8	120
141	Flutamide-Metformin Plus Ethinylestradiol-Drospirenone for Lipolysis and Antiatherogenesis in Young Women with Ovarian Hyperandrogenism: The Key Role of Early, Low-Dose Flutamide. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4716-4720.	1.8	59
142	Opposing Influences of Prenatal and Postnatal Weight Gain on Adrenarche in Normal Boys and Girls. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2647-2651.	1.8	251
143	Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1592-1597.	1.8	161
144	Both intrauterine growth restriction and postnatal growth influence childhood serum concentrations of adiponectin. Clinical Endocrinology, 2004, 61, 339-346.	1.2	30

#	Article	IF	CITATIONS
145	Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Human Reproduction, 2004, 19, 1725-1727.	0.4	40
146	Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. Journal of Pediatrics, 2004, 144, 23-29.	0.9	141
147	Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche. Clinical Endocrinology, 2003, 58, 372-379.	1.2	124
148	Fasting insulin sensitivity and post-oral glucose hyperinsulinaemia related to cardiovascular risk factors in adolescents with precocious pubarche. Clinical Endocrinology, 2003, 59, 756-762.	1.2	17
149	Low-Dose Flutamide-Metformin Therapy Reverses Insulin Resistance and Reduces Fat Mass in Nonobese Adolescents with Ovarian Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2600-2606.	1.8	99
150	Androgen Receptor Gene CAG Repeat Polymorphism in the Development of Ovarian Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3333-3338.	1.8	163
151	Flutamide-Metformin Therapy to Reduce Fat Mass in Hyperinsulinemic Ovarian Hyperandrogenism: Effects in Adolescents and in Women on Third-Generation Oral Contraception. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4720-4724.	1.8	51
152	Hypergonadotrophinaemia with reduced uterine and ovarian size in women born small-for-gestational-age. Human Reproduction, 2003, 18, 1565-1569.	0.4	113
153	Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Human Reproduction, 2003, 18, 57-60.	0.4	54
154	Early Menarche and Subclinical Ovarian Hyperandrogenism in Girls with Reduced Adult Height after Low Birth Weight. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 431-3.	0.4	16
155	Anovulation in Eumenorrheic, Nonobese Adolescent Girls Born Small for Gestational Age: Insulin Sensitization Induces Ovulation, Increases Lean Body Mass, and Reduces Abdominal Fat Excess, Dyslipidemia, and Subclinical Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5702-5705.	1.8	83
156	Additive Effects of Insulin-Sensitizing and Anti-Androgen Treatment in Young, Nonobese Women with Hyperinsulinism, Hyperandrogenism, Dyslipidemia, and Anovulation. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2870-2874.	1.8	109
157	Hypersecretion of FSH in Infant Boys and Girls Born Small for Gestational Age. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1986-1988.	1.8	88
158	Reduced Ovulation Rate in Adolescent Girls Born Small for Gestational Age. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3391-3393.	1.8	133
159	Plasminogen Activator Inhibitor-1 in Girls with Precocious Pubarche: A Premenarcheal Marker for Polycystic Ovary Syndrome?. Pediatric Research, 2002, 51, 244-248.	1.1	30
160	Increased frequency of the G972R variant of the insulin receptor substrate-1 (irs-1) gene among girls with a history of precocious pubarche. Fertility and Sterility, 2002, 78, 1288-1293.	0.5	23
161	Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clinical Endocrinology, 2001, 55, 667-672.	1.2	130
162	Insulin Gene Variable Number of Tandem Repeat Genotype and the Low Birth Weight, Precocious Pubarche, and Hyperinsulinism Sequence. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5788-5793.	1.8	48

#	Article	lF	Citations
163	Early Puberty: Rapid Progression and Reduced Final Height in Girls With Low Birth Weight. Pediatrics, 2000, 106, e72-e72.	1.0	184
164	Adrenal hyperandrogenism in adolescent girls with a history of low birthweight and precocious pubarche. Clinical Endocrinology, 2000, 53, 523-527.	1.2	49
165	Increased Bone Mineral Density and Serum Leptin in Non-Obese Girls with Precocious Pubarche: Relation to Low Birthweight and Hyperinsulinism. Hormone Research in Paediatrics, 2000, 54, 192-197.	0.8	34
166	Reduced Uterine and Ovarian Size in Adolescent Girls Born Small for Gestational Age. Pediatric Research, 2000, 47, 575-577.	1.1	179
167	Exaggerated Adrenarche and Hyperinsulinism in Adolescent Girls Born Small for Gestational Age. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4739-4741.	1.8	190
168	Anovulation after Precocious Pubarche: Early Markers and Time Course in Adolescence1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2691-2695.	1.8	118
169	Pronounced Adrenarche and Precocious Pubarche in Boys. Hormone Research in Paediatrics, 1999, 51, 238-241.	0.8	24
170	Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche. Clinical Endocrinology, 1999, 51, 395-401.	1.2	31
171	Precocious Pubarche, Dyslipidemia, and Low IGF Binding Protein-1 in Girls: Relation to Reduced Prenatal Growth. Pediatric Research, 1999, 46, 320-322.	1.1	49
172	Corticotropin-Releasing Hormone as Adrenal Androgen Secretagogue. Pediatric Research, 1999, 46, 351-353.	1.1	35
173	Insulin Resistance, Premature Adrenarche, and a Risk of the Polycystic Ovary Syndrome (PCOS). Trends in Endocrinology and Metabolism, 1998, 9, 72-77.	3.1	38
174	Growth Hormone Treatment of Short Children Born Small for Gestational Age. Trends in Endocrinology and Metabolism, 1998, 9, 233-237.	3.1	38
175	Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: From a complex constellation to a simple sequence of prenatal onset. Journal of Endocrinological Investigation, 1998, 21, 558-566.	1.8	82
176	Precocious Pubarche, Hyperinsulinism, and Ovarian Hyperandrogenism in Girls: Relation to Reduced Fetal Growth. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3558-3562.	1.8	450
177	Possible genesis of polycystic ovary syndrome in the periadolescent girl. Current Opinion in Endocrinology, Diabetes and Obesity, 1998, 5, 19-26.	0.6	7
178	Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. Fertility and Sterility, 1997, 67, 849-855.	0.5	83
179	Growth hormone, insulin-like growth factor-I axis, and insulin secretion in hyperandrogenic adolescents. Fertility and Sterility, 1995, 64, 1113-1119.	0.5	32